Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065550112> ?p ?o ?g. }
- W2065550112 endingPage "2338" @default.
- W2065550112 startingPage "2329" @default.
- W2065550112 abstract "MOLT-4 (T−), RAJI (B−), and KM-3 (non-B-non-T-, common ALL) malignant lymphoblasts demonstrated significant differences in their activities of purine de novo synthesis (PDNS) and purine salvage pathway and in their cell-kinetic parameters. Incubations with concentrations of methotrexate (0.02 and 0.2 μM), which can be maintained during many hours in the oral maintenance therapy of acute lymphoblastic leukemia, indicated large differences between the three cell lines with respect to the inhibition of PDNS, depencling on the concentration of methotrexate (MTX) and on the activities of the two pathways. These dose- and cell line-dependent differences corresponded to the perturbations of cell-kinetics and purine and pyrimidine (deoxy)ribonucleotide pools in the three cell lines. Exposure of MOLT-4 cells to 0.02 μM MTX resulted in an incomplete inhibition of DNA synthesis in early S phase, as shown by DNA-flow cytometry and increase of dCTP levels, which recovered spontaneously after 48 hr. Almost no impairment of RNA synthesis occurred (unbalanced growth). In RAJI cells, exposed to 0.02 μM MTX, DNA synthesis was delayed in the S phase, not arrested, and RNA synthesis was not impaired, also indicating an unbalanced growth pattern, which, however, did not recover in time. KM-3 cells were arrested in G1 phase and subsequently in early S phase after incubation with 0.02 μM MTX, and perturbations of ribonucleotides indicated a complete inhibition of RNA synthesis, resulting in a balanced growth pattern. Cytotoxicity was more pronounced in KM-3 cells. The reliability of the soft agar colony forming assay after low dose MTX treatment is discussed. Exposure of MOLT-4 and KM-3 cells to 0.2 μM MTX resulted in a complete inhibition of DNA synthesis, with cessation of cell progression through all parts of the cell cycle and arrest in G1 phase. RAJI cells showed an increasing accumulation of cells in G1 phase without complete cessation of cell cycle progression. Perturbations of ribonucleotide pools suggested an inhibition of RNA synthesis in all cell lines, indicating a balanced growth pattern in KM-3 cells and MOLT-4 cells. Increased levels of ribonucleotides after prolonged exposure to 0.2 μM MTX were due to reutilization of purine and pyrimidine precursors from nucleic acid breakdown consuming PRPP, whereas consumption of ribo-nucleotides for RNA synthesis was absent. The perturbations of deoxyribonucleotide pools after exposure to 0.02 and 0.2 μM MTX were in agreement with the changes in DNA-flow cytometry. Increased levels of dCTP after exposure to 0.02 μM MTX correlated with accumulation of cells in early S phase. A consplcuous phenomenon was the absence of decrease in dGTP pools in RAJI cells, in which cytotoxicity was low. Cytotoxicity was correlated with the degree of PDNS inhibition and a severe decrease of both dGTP and dTTP pools. The differences between the T−, B−, and non-B-non-T-, common ALL cell lines with respect to the parameters studied may explain the different responses to treatment of patients with corresponding lymphoid leukemias and lymphomas and suggest possibilities for different treatment strategies." @default.
- W2065550112 created "2016-06-24" @default.
- W2065550112 creator A5014803317 @default.
- W2065550112 creator A5037625247 @default.
- W2065550112 creator A5057530154 @default.
- W2065550112 creator A5070284328 @default.
- W2065550112 creator A5077703605 @default.
- W2065550112 creator A5078287571 @default.
- W2065550112 creator A5082931375 @default.
- W2065550112 date "1988-06-01" @default.
- W2065550112 modified "2023-09-26" @default.
- W2065550112 title "Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages" @default.
- W2065550112 cites W128347512 @default.
- W2065550112 cites W1485382032 @default.
- W2065550112 cites W1561752316 @default.
- W2065550112 cites W1577909961 @default.
- W2065550112 cites W1594621311 @default.
- W2065550112 cites W1605103368 @default.
- W2065550112 cites W1663665741 @default.
- W2065550112 cites W1919645974 @default.
- W2065550112 cites W1964969943 @default.
- W2065550112 cites W1970560187 @default.
- W2065550112 cites W1971035689 @default.
- W2065550112 cites W1985716457 @default.
- W2065550112 cites W1987430097 @default.
- W2065550112 cites W1988838355 @default.
- W2065550112 cites W2000381887 @default.
- W2065550112 cites W2002297908 @default.
- W2065550112 cites W2003098361 @default.
- W2065550112 cites W2004911118 @default.
- W2065550112 cites W2032120204 @default.
- W2065550112 cites W2045104292 @default.
- W2065550112 cites W2054508707 @default.
- W2065550112 cites W2058471639 @default.
- W2065550112 cites W2072365834 @default.
- W2065550112 cites W2072628714 @default.
- W2065550112 cites W2074075942 @default.
- W2065550112 cites W2079867668 @default.
- W2065550112 cites W2081623629 @default.
- W2065550112 cites W2083208920 @default.
- W2065550112 cites W2095029217 @default.
- W2065550112 cites W2134240234 @default.
- W2065550112 cites W2178778111 @default.
- W2065550112 cites W2252416069 @default.
- W2065550112 cites W2266238734 @default.
- W2065550112 cites W2280064868 @default.
- W2065550112 cites W2286532017 @default.
- W2065550112 cites W4245847329 @default.
- W2065550112 cites W64399449 @default.
- W2065550112 doi "https://doi.org/10.1016/0006-2952(88)90359-0" @default.
- W2065550112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2455520" @default.
- W2065550112 hasPublicationYear "1988" @default.
- W2065550112 type Work @default.
- W2065550112 sameAs 2065550112 @default.
- W2065550112 citedByCount "31" @default.
- W2065550112 countsByYear W20655501122013 @default.
- W2065550112 countsByYear W20655501122018 @default.
- W2065550112 countsByYear W20655501122019 @default.
- W2065550112 countsByYear W20655501122020 @default.
- W2065550112 countsByYear W20655501122021 @default.
- W2065550112 countsByYear W20655501122023 @default.
- W2065550112 crossrefType "journal-article" @default.
- W2065550112 hasAuthorship W2065550112A5014803317 @default.
- W2065550112 hasAuthorship W2065550112A5037625247 @default.
- W2065550112 hasAuthorship W2065550112A5057530154 @default.
- W2065550112 hasAuthorship W2065550112A5070284328 @default.
- W2065550112 hasAuthorship W2065550112A5077703605 @default.
- W2065550112 hasAuthorship W2065550112A5078287571 @default.
- W2065550112 hasAuthorship W2065550112A5082931375 @default.
- W2065550112 hasConcept C109246011 @default.
- W2065550112 hasConcept C113842279 @default.
- W2065550112 hasConcept C1491633281 @default.
- W2065550112 hasConcept C153911025 @default.
- W2065550112 hasConcept C169586020 @default.
- W2065550112 hasConcept C181199279 @default.
- W2065550112 hasConcept C203014093 @default.
- W2065550112 hasConcept C2776476023 @default.
- W2065550112 hasConcept C2779321679 @default.
- W2065550112 hasConcept C2781059491 @default.
- W2065550112 hasConcept C29537977 @default.
- W2065550112 hasConcept C54355233 @default.
- W2065550112 hasConcept C552990157 @default.
- W2065550112 hasConcept C55493867 @default.
- W2065550112 hasConcept C62112901 @default.
- W2065550112 hasConcept C64241487 @default.
- W2065550112 hasConcept C81885089 @default.
- W2065550112 hasConcept C86803240 @default.
- W2065550112 hasConcept C88742014 @default.
- W2065550112 hasConceptScore W2065550112C109246011 @default.
- W2065550112 hasConceptScore W2065550112C113842279 @default.
- W2065550112 hasConceptScore W2065550112C1491633281 @default.
- W2065550112 hasConceptScore W2065550112C153911025 @default.
- W2065550112 hasConceptScore W2065550112C169586020 @default.
- W2065550112 hasConceptScore W2065550112C181199279 @default.
- W2065550112 hasConceptScore W2065550112C203014093 @default.
- W2065550112 hasConceptScore W2065550112C2776476023 @default.
- W2065550112 hasConceptScore W2065550112C2779321679 @default.
- W2065550112 hasConceptScore W2065550112C2781059491 @default.